Investor Presentation
genedrive plc
("genedrive" or the "Company")
Investor Presentation
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it will provide a live presentation to accompany the interim results, presented by CEO, David Budd and CFO, Matthew Fowler, on Friday 26 March at 10.00am.
The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet genedrive plc via the following link: https://www.investormeetcompany.com/genedrive-plc/register-investor
Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. No new price sensitive information will be disclosed, and a PDF of the presentation will be uploaded to the Company's website.
For further details please contact:
|
genedrive plc |
+44 (0)161 989 0245 |
|
David Budd: CEO / Matthew Fowler: CFO |
|
|
|
|
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+44 (0)20 7418 8900 |
|
James Steel / Oliver Jackson |
|
|
|
|
|
finnCap (Joint Broker) |
+44 (0)20 7220 0500 |
|
Geoff Nash / Kate Bannatyne / Alice Lane |
|
|
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
+44 (0)20 7933 8780 or genedrive@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
+44 (0)7980 541 893 / +44 (0)7876 741 001 |
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 5 hours ago Origin Enterprises (CDI)
- 5 hours ago Origin Enterprises (CDI)
- 6 hours ago SSP Group
- 7 hours ago Latham (James)
- 7 hours ago LSL Property Services